Acute Kidney Injury Clinical Trial
Official title:
Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney
To study the impact of intra and post-operative Terlipressin infusion on the occurrence of acute kidney injury after LDLT To investigate perioperative Neutrophil Gelatinase Associated Lipocalin (NGAL) changes and study the effect of Terlipressin on NGAL blood levels
The study will be conducted after approval of the local ethics and research committee of
anesthesia, ICU and pain management of both Faculty of Medicine and Liver Institute, Menoufia
University, Egypt. This study will be conducted in Anesthesia Department, National Liver
Institute hospital on patients undergoing liver transplantation. They will be simply
randomized with closed envelopes into two groups. Terlipressin group and Control group. A
written informed consent will be taken from every patient.
Inclusion criteria: Adult living donor liver transplant recipients with no preoperative renal
dysfunction Exclusion criteria: patients with renal insufficiency defined as serum creatinine
> 2 mg/dl and GFR <60 ml/min by isotope scanning of the kidney.
Anesthetic Technique:
All patients will be monitored by electrocardiography, noninvasive and invasive arterial
blood pressure, pulse oximetry, capnography, fraction inspired oxygen concentration (FiO2).
After preoxygenation, general anesthesia will be induced with Propofol 2 mg/kg IV, Fentanyl 2
µg/kg IV and Rocronium 0.9 mg/kg IV followed by endotracheal intubation and maintenance with
a mixture of air, oxygen 50% with Desflurane. Mechanical ventilation will be adjusted to
maintain end-tidal CO2 between 35-40 mmHg. Central venous line will be inserted for
monitoring of central venous pressure (CVP) with ultrasonography guidance.
The esophageal Doppler probe will then be inserted orally and positioned approximately 35-40
cm from the teeth (CardioQTM®, Deltex Medical, Chichester, UK). Normothermia (core
temperature > 36°C) will be maintained intraoperatively using forced warming air blanket
(Bair Hugger®; Arizant, UK).
After induction of anesthesia patients will be randomly divided into two groups Terlipressin
group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be
started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively. In the
control group, continuous placebo infusion will be started. The Anesthesia team will be kept
blind to the contents of the infusion.
Rotetional thromboelastometry [ROTEM] will guide intraoperative blood transfusion protocol as
prescribed by the study of Gorlinger K will be followed in both groups. (13) Platelets will
be substituted when maximum clot firmness of (MCF EXTEM) <45mm and maximum clot firmness of
FIBTEM (MCF FIBTEM) >8mm.
Fresh frozen plasma will be administerd when clot formation time representing extrinsic
coagulation pathway (CFT EXTEM) was >240sec. Hematocrite will be kept more than or equal to
25 with packed red blood cells units.
All patients will receive intraoperative methylprednisolone (10 mg/kg). Hemodynamics will be
maintained, keeping mean blood pressure above 60 mmHg by fluids and vasoactive drugs.
After surgery, all patients will be transferred to the intensive care unit for controlled
mechanical ventilation. The patients will be extubated when hemodynamics are stable, liver
graft functions satisfactory, sufficient spontaneous breathing, and core temperature >36°C.
Measured Parameters:
-Evaluation of renal function and injury:
- Serum Cr levels and BUN will be determined preoperatively and then daily up to 5 days
after surgery.
- The glomerular filtration rate (GFR) or the nearest approximation of GFR will be
calculated from the equation of modification of Diet in Renal Disease Study on the basis
of obtained serum Cr levels and patient demographics.
- Urine output
- Determination of NGAL Blood samples for the determination of NGAL will be drawn at 3
different time points: immediately after the induction of anesthesia, 2 hours after
reperfusion, and 24 hours after reperfusion.
Blood samples will be drawn at the predetermined time points and processed within 2 hours
after collection. Serum will be collected and subsequently frozen at -80°Celsius until
further analysis -Hemodynamic parameters:
• Heart rate, mean arterial blood pressure [MABP], and CVP, cardiac output (COP), stroke
volume (SV), corrected flow time (FTc), systemic vascular resistance (SVR) will be recorded
after induction of anesthesia, then every hour during the operation.
Other parameters:
- Anhepatic phase time, warm and cold ischemia time.
- Graft weight , recipient graft body weight ratio.
- Fluid, blood product transfusion.
- Blood glucose level, postoperative complication.
- ICU stay, length of hospital stay.
- 30 days mortality The need for postoperative renal replacement therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |